Morgan Stanley Cytom X Therapeutics, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 319,288 shares of CTMX stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

319,288

Previous 339,206 5.87%

Holding current value

$1.23 Million

Previous $769,000 32.38%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.76 - $3.23 $35,055 - $64,335	-19,918 Reduced 5.87%	319,288 $1.02 Million
Q2 2025 Aug 15, 2025	BUY	$0.43 - $2.99 $119,807 - $833,079	278,622 Added 459.89%	339,206 $769,000
Q1 2025 May 15, 2025	BUY	$0.58 - $1.14 $27,482 - $54,016	47,383 Added 358.93%	60,584 $38,000
Q4 2024 Feb 14, 2025	SELL	$0.86 - $1.29 $31,963 - $47,945	-37,167 Reduced 73.79%	13,201 $13,000
Q3 2024 May 14, 2025	SELL	$1.12 - $1.51 $154,692 - $208,558	-138,118 Reduced 73.28%	50,368 $59,000

Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.51 $154,692 - $208,558	-138,118 Reduced 73.28%	50,368 $59,000
Q2 2024 May 14, 2025	BUY	$1.21 - $5.13 $212,094 - $899,212	175,285 Added 1327.82%	188,486 $229,000
Q2 2024 Oct 17, 2024	SELL	$1.21 - $5.13 $807,672 - $3.42 Million	-667,498 Reduced 77.98%	188,486 $229,000
Q2 2024 Aug 14, 2024	SELL	$1.21 - $5.13 $807,672 - $3.42 Million	-667,498 Reduced 77.98%	188,486 $229,000
Q1 2024 Oct 17, 2024	BUY	$1.41 - $2.74 $941,172 - $1.83 Million	667,498 Added 354.14%	855,984 $1.87 Million
Q1 2024 Aug 16, 2024	BUY	$1.41 - $2.74 $1.1 Million - $2.13 Million	777,063 Added 984.61%	855,984 $1.87 Million
Q1 2024 May 15, 2024	BUY	$1.41 - $2.74 $1.1 Million - $2.13 Million	777,063 Added 984.61%	855,984 $1.87 Million
Q4 2023 Aug 16, 2024	SELL	$1.07 - $1.55 $117,234 - $169,825	-109,565 Reduced 58.13%	78,921 $122,000
Q4 2023 Feb 13, 2024	BUY	$1.07 - $1.55 $16,329 - $23,654	15,261 Added 23.97%	78,921 $122,000
Q3 2023 Nov 15, 2023	SELL	$1.26 - $1.87 $25,976 - $38,551	-20,616 Reduced 24.46%	63,660 $82,000
Q2 2023 Aug 14, 2023	SELL	$1.41 - $1.92 $94,609 - $128,830	-67,099 Reduced 44.33%	84,276 $144,000
Q1 2023 May 15, 2023	BUY	$1.48 - $2.88 $197,470 - $384,266	133,426 Added 743.36%	151,375 $228,000
Q4 2022 Feb 14, 2023	BUY	$1.19 - $1.91 $3,446 - $5,531	2,896 Added 19.24%	17,949 $28,000
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $180,032 - $288,344	-146,368 Reduced 90.67%	15,053 $22,000
Q2 2022 Oct 27, 2022	BUY	$1.53 - $2.89 $128,163 - $242,086	83,767 Added 107.87%	161,421 $295,000
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $128,163 - $242,086	83,767 Added 107.87%	161,421 $295,000
Q1 2022 Oct 27, 2022	SELL	$2.67 - $4.68 $223,657 - $392,029	-83,767 Reduced 51.89%	77,654 $206,000
Q1 2022 May 13, 2022	SELL	$2.67 - $4.68 $25,602 - $44,876	-9,589 Reduced 10.99%	77,654 $206,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $119,927 - $229,008	-30,989 Reduced 26.21%	87,243 $376,000
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $510,762 - $760,231	118,232 New	118,232 $601,000

Others Institutions Holding CTMX

# of Institutions

109

Shares Held

121M

Call Options Held

1.49M

Put Options Held

258K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $255M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account